The Ketamine Clinics Winning Psychiatrist Referrals Are the Ones Sending Scores Back
Most ketamine clinics compete on the same few things. Price, location, reviews and how fast a new patient can get a chair. All of those can be copied by the clinic down the street within a quarter. Documented outcomes cannot. Plenty of clinics already collect PHQ-9 scores. Far fewer can state a response rate from them. Fewer still send anything back to the doctor who made the referral. A clinic that can state its response rate from its own records owns something a competitor needs years to build.
Measurement costs staff time, and staff time costs margin. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The moat | A multiyear record of standardized scores is the one asset a new competitor cannot buy or copy |
| The evidence | Measurement-based care improved response and remission in a randomized depression trial |
| The adoption gap | A JAMA Psychiatry review found typically less than 20% of behavioral health clinicians use it |
| Who it persuades | Referring clinicians, payers preparing for psychedelic coverage, and acquirers |
| The benchmark | CMS already defines depression remission as a PHQ-9 below 5 at twelve months |
| The cost of waiting | The value compounds with every documented patient, so a late start never catches up |
Every Clinic Says Its Outcomes Are Good
Clinic websites are full of the same language. Life changing results. High success rates. Patients who finally feel like themselves again.
Nobody believes it, because everybody says it. A referring psychiatrist cannot tell those claims apart. Neither can a payer, a buyer or a patient comparing three clinics in one city.
The claim only becomes an asset when a number sits behind it. That number has to come from a standardized instrument, collected the same way for every patient, over enough time to mean something.
The Clinical Case Came First
Measurement-based care means scoring symptoms with a validated scale and using the scores to guide treatment. It is not a new idea, and the evidence for it is solid.
A randomized trial in the American Journal of Psychiatry compared it with standard care for major depression. Response reached 86.9% with measurement-based care versus 62.7%. Remission reached 73.8% versus 28.8%.
That trial studied oral antidepressants in outpatients in Beijing, not ketamine. The mechanism still applies. Scores flag the patients who are not improving early enough to change course.
Adoption has lagged anyway. A review in JAMA Psychiatry found that typically less than 20% of behavioral health practitioners integrate it into their practice. That gap is the opportunity.
The Referral Case
Most psychiatrists and primary care physicians who refer a patient never hear what happened. The patient disappears into a cash pay clinic, and the referring clinician has no idea whether it worked.
A clinic that sends back a short report changes that relationship. Intake PHQ-9, score after the induction series, score at follow up. It takes minutes to produce once the data exists.
Referring clinicians send patients where they can see results. A report on their own patients is more persuasive than any lunch or brochure, because it answers the question they actually have.
Aggregate numbers help with visibility too. Specific, sourced figures are the kind of content that AI search tools tend to cite when patients ask where to go.
The Payer Case
Payers are starting to prepare for psychedelic medicine. We covered an insurance trade publication urging insurers to get ready, and a Medicaid coverage report from the Center for Health Care Strategies.
Coverage conversations run on data. A plan deciding whether to contract with a clinic will want to know what happens to its members, and a clinic without scores has nothing to show.
CMS already has a yardstick. Its Depression Remission at Twelve Months measure counts adults who start with a PHQ-9 above 9 and score below 5 about a year later.
Most cash pay ketamine clinics will never report that measure. But a clinic collecting PHQ-9 at intake and at follow up is already capturing the data a payer recognizes. The format is not something to invent.
There is also a competitive angle. Compass has said it has collaborations with more than 1,000 sites that already deliver Spravato, ahead of a possible psilocybin approval. Clinics that can document outcomes will be easier partners for manufacturers and plans alike.
The Exit Case
Buyers underwrite records. We laid out the full acquisition readiness checklist earlier this year, and outcomes data was on it for a reason.
A roll up that aggregates documented response rates across many clinics has something no single clinic can offer a payer or pharma partner. That is why the next wave of consolidation should price outcomes data as an asset.
A clinic with three years of clean scores brings that asset to the table. A clinic without them brings testimonials, and testimonials do not transfer.
Why It Cannot Be Rushed
This is what makes it a moat rather than a feature. A competitor can match a price tomorrow. A competitor can open a location next year.
Nobody can go back and collect a twelve month follow up score for a patient treated last year. The record only exists if someone started collecting it at the time.
That means the clinic that starts this month will always be ahead of the clinic that starts next year. The lead does not shrink. It grows with every patient.
What a Minimum Program Looks Like
This does not require an expensive platform. The Joint Commission’s measurement-based care standard for behavioral health organizations offers a useful frame even for unaccredited clinics.
It asks for three things. Use a standardized instrument to track each patient. Use the results to adjust the treatment plan. Aggregate the data to evaluate outcomes across the population served.
For a ketamine clinic, that translates into a short list:
Pick the instruments. PHQ-9 for depression and GAD-7 for anxiety cover most patients. Add a pain scale for chronic pain programs.
Fix the schedule. Intake, end of induction, and set follow ups. Our integration guide suggests 30, 60 and 90 days.
Store it where it can be counted. Scores buried in visit notes are not data. A structured field or even a disciplined spreadsheet is.
Track who drops out. Patients who stop responding to follow ups are part of the result. Leaving them out inflates the number and destroys its credibility.
Review it quarterly. Look at response rates by protocol and by provider. The clinic learns something, and the report writes itself.
The Bottom Line
Outcomes tracking gets sold as quality improvement. It is also the most defensible business asset a ketamine clinic can build.
It helps win referrals, it gives a clinic something to bring to a payer, and it holds value in a sale. None of that works without years of consistent collection, which is exactly why it is hard to copy.
Patients comparing options can start with our directory of verified ketamine clinics.
